Esperion Therapeutics, Inc. (ESPR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.180.00%
Close 2026-07-13 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ESPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -57.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 6.3% |
Growth built into the price is above our model estimate.
The price assumes 63.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
ESPR — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continuing
Dated 2026-07-13
Notice of Delisting or Failure to Satisfy a Continuing Listing Rule or Standard; Transfer of Listing. In connection with the consummation of the Merger, on July 13, 2026, the Company (i) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq file with the Securities and Exchange Commission (the “SEC”) a Notification of Removal from Listing and/or Registration on Form 25 to delist and deregister the shares of Common Stock under Section…
Why it matters: The deal ties a possible $60 million payment to this sales mark. It also tests uptake of Esperion's acquired product.
Supportive ifA company filing reports ENBUMYST U.S. net sales of at least $160 million in one calendar year by December 31, 2030.
Worry ifA company filing reports ENBUMYST U.S. net sales below $160 million in every calendar year through December 31, 2030.
Why it matters: The merger deal ties up to $40 million in payments to 2027 U.S. sales of products with bempedoic acid.
Supportive ifReported 2027 U.S. net sales of NEXLETOL, NEXLIZET, and other covered products exceed $300 million. Sales above $350 million trigger the full $40 million payment.
Worry ifReported 2027 U.S. net sales of covered bempedoic acid products are $300 million or less, with no payment under this milestone.
Why it matters: Esperion agreed to a $3.16 cash payment per share, plus possible sales-based payments. Closing ends its public listing.
Watch forA filing confirms the merger closed. Esperion became privately held, and its shares left Nasdaq.
Also watch forA filing reports the merger agreement ended or closing conditions were not met.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$32 on $10,000 · ±0.3% | How much price usually moves either way. |
| Bad day | $728 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,319 loss on $10,000 · 53.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.